625095-57-0

Basic information

• Product Name: (S)-1-(3-Chlorophenyl)-1,3-propanediol
• Synonyms: (S)-1-(3-Chlorophenyl)-1,3-propanediol;(S)-1-(3-chlorophenyl)propane-1,3-diol
• CAS NO: 625095-57-0
• Molecular Formula: C₉H₁₁ClO₂
• Molecular Weight: 186.63544
• Mol File: 625095-57-0.mol

Chemical Properties

• Melting Point: 142-144 °C
• Boiling Point: 345.3±27.0 °C(Predicted)
• Appearance: /
• Density: 1.274±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Store in freezer, under -20°C
• PKA: 13.68±0.20(Predicted)
• CAS DataBase Reference: (S)-1-(3-Chlorophenyl)-1,3-propanediol(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-1-(3-Chlorophenyl)-1,3-propanediol(625095-57-0)
• EPA Substance Registry System: (S)-1-(3-Chlorophenyl)-1,3-propanediol(625095-57-0)

Safety Data

• Hazardous Substances Data: 625095-57-0(Hazardous Substances Data)

Usage

Uses

Used in Personal Care Products:
Triclosan is used as an active ingredient in personal care products such as soaps, toothpaste, and hand sanitizers for its ability to kill or prevent the spread of harmful microorganisms, thereby promoting hygiene and reducing the risk of infections.
Used in Industrial and Medical Applications:
In certain industrial and medical settings, triclosan is employed as an antibacterial and antifungal agent to ensure the cleanliness and sterility of equipment, surfaces, and materials that come into contact with humans or are used in medical procedures.
However, it is important to note that there is ongoing debate and research regarding the potential health and environmental concerns associated with triclosan. These concerns include its possible contribution to antibiotic resistance and disruption of hormone regulation in humans and wildlife. As a result, some jurisdictions have implemented regulations or bans on its use in certain products.

Upstream product

• 625095-56-9 (S)-(-)-(3-chlorophenyl)-3-hydroxypropionic acid 
• 51699-45-7 (S)-(-)-1-(3'-Chlorophenyl)-1,3-Propanediol 
• 618-46-2 m-Chlorobenzoyl chloride 
• 33167-21-4 3-(3-chloro-phenyl)-3-oxo-propionic acid ethyl ester 
• 587-04-2 m-Chlorobenzaldehyde 
• 99-02-5 3'-Chloroacetophenone 
• 40620-64-2 3-hydroxy-3-(3'-chlorophenyl)propionic acid 
• 108-05-4 vinyl acetate 
• 135505-20-3 (S)-(-)-methyl 3-(3-chlorophenyl)-3-hydroxypropanoate 
• 632327-19-6 methyl 3-(3-chlorophenyl)-3-oxopropanoate 
• 804560-96-1 (+/-)-1-(1,3-bistrimethylsilyloxypropyl)-3-chlorobenzene 
• 13422-80-5 3-(3-chlorophenyl)-3-oxopropanoic acid 
• 51699-40-2 3-(3-chlorophenyl)-3-hydroxypropionic acid ethyl ester 
• 804561-30-6 (2S,8R,11S)-2-(3-chlorophenyl)-8-methyl-11-(1-methylethyl)-1,5-dioxaspiro[5.5]undecane 

Downstream Products

• 693223-08-4 (4S)-(-)-trans-2-(4-nitrophenoxy)-2-oxo-4-(3-chlorophenyl)-1,3,2-dioxaphosphorinane 
• 883989-35-3 (4S)-4-(3-chlorophenyl)-2-(4-nitrophenoxy)-1,3,2-dioxaphosphinane-2-oxide 
• 625095-60-5 (+)-cis-9-{2-[4-(S)-(3-chlorophenyl)-2-oxo-1,3,2-dioxaphosphorinan-2-methyleneoxy]eth-1-yl}adenine 
• 693223-03-9 (+)-cis-5'-O-[4-(S)-(3-chlorophenyl)-2-oxo-1,3,2-dioxaphosphorinan-2-yl]cytosine-1-β-D-arabinofuranoside 
• 804561-62-4 2',3'-di-O-tert-butyldimethylsilyl-5'-O-cis-[4-(S)-(3-chlorophenyl)-2-oxo-1,3,2-dioxaphoshorinan-2-yl]cytosine-1-β-D-arabinofuranoside 
• 625095-67-2 C₁₃H₁₅ClO₄ 
• 625095-68-3 C₁₃H₁₅ClO₄ 
• 883989-27-3 (±)-4-(3-chlorophenyl)-2-(4-nitrophenoxy)-1,3,2-dioxaphosphinane-2-oxide 
• 852948-13-1 [14C]-MB07811 

Relevant articles and documents

PHENANTHROLINE PHOSPHONIC ACID DERIVATIVE AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF

The present invention relates to a novel phenanthroline phosphonic acid compound and a pharmaceutical salt thereof, as well as an application of the compound and the pharmaceutical salt thereof as collagen prolyl hydroxylase inhibitors in the preparation of drugs for preventing or treating collagen prolyl-4-hydroxylase related disease.

Synthesis of α,β-unsaturated δ-lactones by vinyl acetate mediated asymmetric cross-aldol reaction of acetaldehyde: Mechanistic insights

A tandem asymmetric cross-aldol reaction involving the in situ generation of acetaldehyde from vinyl acetate has been developed that may resolve the challenges associated with the handling of acetaldehyde. The simple protocol, mild reaction conditions and unique harmony of an organocatalyst with a biocatalyst make this method a valuable tool for the synthesis of asymmetric β-hydroxy aldehydes. By using this methodology we have accessed α,β-unstaurated δ-lactones as well as isochromenones with high enantioselectivities from both asymmetric β-hydroxy aldehydes and ketones. Systemic density functional theory (DFT) studies were also performed to gain mechanistic insights into the role of hydrogen bonding in the asymmetric cross-aldol reaction of acetaldehyde and in the key cis/trans isomerisation step in the synthesis of δ-lactones. Copyright

Design, Synthesis, and Sustained-Release Property of 1,3-Cyclic Propanyl Phosphate Ester of 18β-Glycyrrhetinic Acid

A new class of potential prodrugs, 1,3-cyclic propanyl phosphate esters of 18β-glycyrrhetic acid, was designed and synthesized through the key reaction of 18β-glycyrrhetic acid with 1,3-cyclic propanyl phosphate ester catalysed by lithium diisopropylamide

Pradefovir: A prodrug that targets adefovir to the liver for the treatment of hepatitis B

Adefovir dipivoxil, a marketed drug for the treatment of hepatitis B, is dosed at submaximally efficacious doses because of renal toxicity. In an effort to improve the therapeutic index of adefovir, 1-aryl-1,3-propanyl prodrugs were synthesized with the r

NOVEL 2'-C-METHYL AND 4'-C-METHYL NUCLEOSIDE DERIVATIVES

Novel 2'-C-methyl nucleoside 5 '-monophosphate and 4'-C-methyl nucleoside 5'- monophosphate derivatives, stereoisomers, and pharmaceutically acceptable salts or prodrugs thereof, their preparation, and their uses for the treatment of hepatitis C viral inf

Phosphoramidate and phosphate prodrugs of (-)-β-D-(2R,4R)-dioxolane- thymine: Synthesis, anti-HIV activity and stability studies

A series of phosphoramidate and phosphate prodrugs of DOT were synthesized via dichlorophosphate or H-phosphonate chemistry and evaluated for their anti-HIV activity against LAI M184V mutants in PBM cells as well as for their cytotoxicity. The antiviral and cytotoxic profiles of the prodrugs were compared with that of the parent compound (DOT), and it was found that four aryl phosphoramidates 5, 18, 20, and 26 showed a significant enhancement (8- to 12-fold) in anti-HIV activity without cytotoxicity. Chemical stability of these prodrugs was evaluated in phosphate buffer at pH values of biological relevance (i.e., pH 2.0 and 7.4). Enzymatic hydrolysis was also studied in esterase or lipase in buffer solution. Chemical stability studies indicate that the phosphoramidates have good chemical stability at pH 2.0 and at pH 7.4 phosphate buffer. Phosphoramidate prodrugs were hydrolyzed in vitro by esterase or lipase and found to be better substrates for lipases than for esterases. 1,3-Diol cyclic phosphates showed potent anti-HIV activity without increasing the cytotoxicity compared with that of DOT and have good chemical and enzymatic stability. Long-chain lipid phosphates, although showed potent anti-HIV activity, exhibited increased cytotoxicity.

LEWIS ACID MEDIATED SYNTHESIS OF CYCLIC ESTERS

Methods for the synthesis of cyclic phosphonic acid diesters from 1,3-diols are described, whereby cyclic phosphonic acid diesters are produced by reacting a chiral 1,3-diol and an activated phosphonic acid in the presence of a Lewis acid.

Novel 2'-C-methyl nucleoside derivatives

Compounds of Formula I, stereoisomers, and pharmaceutically acceptable salts or prodrugs thereof, their preparation, and their uses for the treatment of hepatitis C viral infection are described:

Design, Synthesis, and Characterization of a Series of Cytochrome P 450 3A-Activated Prodrugs (HepDirect Prodrugs) Useful for Targeting Phosph(on)ate-Based Drugs to the Liver

A new class of phosphate and phosphonate prodrugs, called HepDirect prodrugs, is described that combines properties of rapid liver cleavage with high plasma and tissue stability to achieve increased drug levels in the liver. The prodrugs are substituted c

Process for preparation of cyclic prodrugs of PMEA and PMPA

The method of preparing compounds of Formula I is described: wherein: M and V are cis to one another and MPO3H2 is a phosphonic acid selected from the group consisting of 9-(2-phosphonylmethoxyethyl)adenine, and (R)-9-(2-phosphonylmethoxypropyl)adenine; wherein V is phenyl, optionally substituted with 1-2 substituents selected from a group consisting of fluoro, chloro, and bromo; comprising: coupling a chiral 1-phenylpropane-1,3-diol, wherein the phenyl may be optionally substituted, with MPOCl2 or an N-6 substituted analogue thereof. Additionally, methods and salt forms are described that enable isolation and purification of the desired isomer.